Biomarker Results from PEVENAZA, a Randomized Phase 2 Study of Venetoclax and Azacitidine +/- Pevonedistat in Newly Diagnosed AML Patients Unfit for Intensive Chemotherapy: Increased Efficacy in a Subset of Patients with IDH1/2 Mutations and Other Observations
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined